ASCO has been working in parallel with various other institutions to generate a patient-centered oncology payment reform model.
ASCO recently submitted comments to the Centers for Medicare and Medicaid Innovation (CMMI)—a component of the Centers for Medicare & Medicaid Services (CMS)—regarding the center’s proposed cancer care payment and service delivery model, Preliminary Design for an Oncology Focused Model (OCM). ASCO offered specific recommendations for the proposed model and highlighted areas where clarification or refinement may be needed.
The CMMI model relies on adjustments to the current fee for service payment system, attempting to control costs while maintaining quality of care. In its September 18, 2014, letter, ASCO supported the inclusion of OCM among the payment reform models that will be tested to determine new approaches to payment for oncology care; however, ASCO also urged the center to test models that include more fundamental reform that moves away from fee for service—a “change many oncology practices believe is vital to sustaining a robust cancer care delivery system.”
ASCO offered recommendations on several aspects of OCM, such as quality measurement and improvement, risk adjustment, emergency department visits and hospitalizations, clinical trials, and mortality rates as a measure of performance. The society further stressed that in order to be meaningful, the incentives embedded in OCM must come from decisions that are under the control of the oncology practice, that performance measures must be robust and applicable to the patient population, and that the overall system must reflect the variability in labor and resources required to treat patients with cancer.
ASCO's press release: http://bit.ly/1ugOgZA
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More